



## Presentation Titles and Learning Objectives – Sterile Compounding In-Person Training

### Module 1 Non-HD Sterile Compounding: 16.5 CE hours

Lecture or Practical Knowledge Check (PKC)	Learning Objectives
<p>Introduction of Compounding (Lecture 1) <b>Melanie Dorey and Mary Nazzal</b> 60 mins</p>	<ol style="list-style-type: none"><li>1. Describe the historical events and key developments in the evolution of sterile compounding in the United States.</li><li>2. Review the roles of organizations responsible for implementing and enforcing sterile compounding standards in the US.</li><li>3. Differentiate between compounding pharmacy, 503B outsourcing pharmacy, and manufacturing.</li><li>4. Explain the importance of high-quality standards in sterile compounding and how they apply to practice.</li></ol>



<p>Quality Assurance (Lecture 2)</p> <p>Mary Nazzal</p> <p>60 mins</p>	<ol style="list-style-type: none"><li>1. Differentiate between quality assurance and quality control in the context of sterile compounding.</li><li>2. List the USP 797 (2023) requirements related to quality assurance, documentation, and standard operating procedures (SOPs).</li><li>3. Describe the roles of the designated person and compounding staff in relation to quality assurance, documentation, and SOPs.</li><li>4. Explain how to develop a robust document control system for SOPs.</li><li>5. Identify the critical elements during a recall and incident management process.</li></ol>
<p>Training and Competency Assessments (Lecture 3)</p> <p>Mary Nazzal</p> <p>60 mins</p>	<ol style="list-style-type: none"><li>1. Review the training and competency assessment requirements outlined in USP 797 (2023).</li><li>2. Discuss best practice recommendations for training and conducting competency assessments.</li><li>3. Identify the documentation requirements for training and assessment results, and how to effectively communicate these with compounding personnel.</li><li>4. Explain the importance of supervision in ensuring compounding staff competency.</li><li>5. Describe various methods for training and competency assessments.</li></ol>



<p>Inventory, Storage, Verification, and Packaging (Lecture 4)</p> <p>Melanie Dorey</p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Explain key considerations for sourcing appropriate components for preparing compounded sterile preparations (CSPs).</li><li>2. Describe the USP 797 (2023) requirements for the storage of components and CSPs.</li><li>3. Identify the verification steps required during compounding and the final verification for CSPs.</li><li>4. Outline the requirements for packaging and transporting CSPs according to USP 797 (2023).</li></ol>
<p>Assigning Beyond-Use Dates (Lecture 5)</p> <p>Mary Nazzal</p> <p>60 mins</p>	<ol style="list-style-type: none"><li>1. Define the requirements for the use of commercially available single-dose containers (SDCs), multiple-dose containers (MDCs), and pharmacy bulk packages.</li><li>2. Identify the compounding categories and associated beyond-use date (BUD) limits per USP 797 (2023).</li><li>3. Recognize situations that are classified as "not compounding."</li><li>4. Define immediate-use compounding and its applicable scenarios.</li><li>5. Contrast potency testing with stability-indicating methods for assessing drug stability.</li></ol>



<p>Practical Knowledge Check: Quality Assurance and Beyond-use Dates (Lab 1)</p> <p>Mary Nazzal and Melanie Dorey</p> <p>30 mins</p>	<ol style="list-style-type: none"><li>1. Identify appropriate evidence-based sources of information for developing a master formulation record.</li><li>2. Assess the assignment of BUDs to CSPs following USP 797 (2023) and evidence-based information.</li><li>3. Describe the key differences between a compounding record and a master formulation record (MFR).</li><li>4. Evaluate compliance with a quality assurance program per USP 797 (2023).</li></ol>
<p>Engineering Controls (SEC and PEC) (Lecture 6)</p> <p>Jake Warden</p> <p>90 mins</p>	<ol style="list-style-type: none"><li>1. Identify primary engineering controls (PECs) and the secondary engineering controls (SECs) in which they are placed.</li><li>2. Define the USP 797 (2023) standards for non-hazardous drug (non-HD) PECs and SECs.</li><li>3. Discuss best practice recommendations for designing secondary engineering controls.</li><li>4. Explain the maintenance requirements for engineering controls.</li></ol>
<p>Practical Knowledge Check: Certification (Lab 2)</p> <p>Jake Warden, Melanie Dorey, and Mary Nazzal</p> <p>60 mins</p>	<ol style="list-style-type: none"><li>1. Describe the certification tests performed in SECs and PECs within a non-HD sterile compounding environment.</li><li>2. Define the certification requirements for SECs and PECs per USP 797 (2023).</li><li>3. Identify key reporting elements found in certification reports and discuss how to address deviations.</li></ol>



<p>Environmental Monitoring (EM) (Lecture 7)</p> <p><b>Christine Hong</b></p> <p>60 mins</p>	<ol style="list-style-type: none"><li>1. Discuss the purpose of an environmental monitoring program, including the identification of action levels for microbial growth.</li><li>2. Determine the requirements of an environmental monitoring program per USP 797 (2023).</li><li>3. Explain the appropriate types of sampling media used for air and surface sampling.</li><li>4. Define the course of action when samples exceed the action level.</li></ol>
<p>Practical Knowledge Check: Performing Air and Surface Viable Monitoring (Lab 3)</p> <p><b>Christine Hong and Melanie Dorey</b></p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Develop an environmental monitoring program.</li><li>2. Determine the locations and steps for conducting viable air and surface sampling.</li><li>3. Explain the appropriate use of equipment and supplies for air and surface sampling.</li></ol>
<p>Practical Knowledge Check: EM Investigation and Remediation (Lab 4)</p> <p><b>Christine Hong and Melanie Dorey</b></p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Identify common issues found with environmental monitoring sampling plans and results in non-HD anteroom and clean room suites.</li><li>2. Explain the key components for investigating and remediating environmental excursions.</li><li>3. Provide suggestions for investigation and remediation strategies.</li></ol>



<p>Gloved Fingertip Sampling and Media Fill Testing (Lecture 8)</p> <p>Melanie Dorey</p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Differentiate between the USP 797 (2023) requirements and best practice recommendations for personnel gloved fingertip sampling and media fill testing.</li><li>2. Describe the integration of media-fill testing, surface sampling, and subsequent gloved fingertip sampling as best practices.</li><li>3. Determine the importance of using media-fill testing to verify the aseptic technique skills of compounding staff.</li><li>4. Explain the required corrective actions and additional training in the event of test failures.</li></ol>
<p>Cleaning and Disinfecting (Lecture 9)</p> <p>Melanie Dorey</p> <p>60 mins</p>	<ol style="list-style-type: none"><li>1. Develop strategies address for contamination control issues.</li><li>2. Explain the USP 797 (2023) requirements for cleaning and disinfection in a sterile compounding environment.</li><li>3. Describe best practice recommendations for cleaning and disinfection in a sterile compounding environment.</li><li>4. Identify the types of agents and supplies to use during cleaning and disinfection.</li><li>5. Outline the SOPs, training, competency, and documentation requirements for cleaning and disinfection.</li></ol>



<p>Contamination Control Principle: Hand Hygiene and Garbing (Lecture 10)</p> <p>Melanie Dorey</p> <p>60 mins</p>	<ol style="list-style-type: none"><li>1. Determine hand hygiene and garbing procedures that meet USP 797 (2023) standards.</li><li>2. Discuss best practice recommendations for performing hand hygiene and garbing procedures.</li><li>3. Identify the requirements and best practice recommendations for personal protective equipment (PPE) and cleanroom garb used during hand hygiene and garbing procedures.</li><li>4. Compare the sequence of hand hygiene and garbing in a cleanroom suite versus a segregated compounding area (SCA).</li></ol>
<p>Contamination Control Principle: Material Handling &amp; Operator Conduct (Lecture 11)</p> <p>Melanie Dorey</p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Review contamination control principles that affect the state of microbial control.</li><li>2. Discuss material handling procedures per USP 797 (2023).</li><li>3. Identify the types of cleaning agents to use during material handling procedures.</li><li>4. Explain the USP 797 (2023) requirements and best practice recommendations for compounder conduct in a sterile compounding environment.</li></ol>



<p>Contamination Control Principle: Aseptic Technique (Lecture 12)</p> <p><b>Melanie Dorey</b></p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Identify best practice recommendations for aseptic technique and promoting patient safety.</li><li>2. Define the importance of proper setup of equipment and supplies and good aseptic technique in reducing the risk of contamination.</li><li>3. Discuss the requirements for aseptic technique per USP 797 (2023).</li><li>4. Describe the proper way to move items in and out of the PEC.</li></ol>
<p>Practical Knowledge Check: Applying Contamination Control Principles in the Cleanroom (Lab 5)</p> <p><b>Melanie Dorey and Mary Nazzal</b></p> <p>90 mins</p>	<ol style="list-style-type: none"><li>1. Assess the attendee's ability to perform all necessary contamination control principles to prepare a CSP.</li><li>2. Evaluate the knowledge necessary to prevent contamination of the environment and CSPs.</li></ol>
<p>Technology in the Cleanroom (Lecture 13)</p> <p><b>Melanie Dorey</b></p> <p>30 mins</p>	<ol style="list-style-type: none"><li>1. Identify the types of technology and devices used in sterile compounding areas.</li><li>2. Describe the USP 797 (2023) requirements for introducing technology, devices, and equipment into the anteroom and cleanroom.</li><li>3. Determine best practice recommendations for cleaning, installing, and using technology devices and equipment in the cleanroom.</li><li>4. Discuss the challenges associated with planned and unplanned downtime, cyberattacks, etc., and their impact on the cleanroom.</li></ol>





## Module 2 HD Sterile Compounding: 11 CE hours

Lecture or Practical Knowledge Check (PKC)	Learning Objectives
<p>Handling Hazardous Drugs and Standards to Prevent Harm (Lecture 1)</p> <p>Fred Massoumi</p> <p>60 mins</p>	<ol style="list-style-type: none"><li>1. Describe the history and development of USP 800 standards for compounding hazardous drugs.</li><li>2. Provide examples of the effects of HD exposure on healthcare workers.</li><li>3. Discuss key strategies to prevent healthcare worker exposure to HDs.</li><li>4. Describe the requirements for hazardous drug compounding facilities.</li></ol>



<p>Assessment of Risk (Lecture 2)</p> <p>Mary Nazzal</p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Define the components required in an assessment of risk per USP 800.</li><li>2. Evaluate different approaches for creating and maintaining an assessment of risk.</li><li>3. Discuss specific examples of alternative handling strategies from actual practice.</li></ol>
<p>Containment Engineering Controls (Lecture 3)</p> <p>Jake Warden</p> <p>75 mins</p>	<ol style="list-style-type: none"><li>1. Identify containment primary engineering controls (C-PECs) and the controlled areas in which they are placed.</li><li>2. Outline the USP 800 requirements for C-PECs and controlled areas.</li><li>3. Discuss best practice recommendations for designing containment-controlled compounding areas.</li><li>4. Describe different types of C-PECs and the differences between them.</li></ol>
<p>Interactive: Problem Solving Downtime Issues with Engineering Controls (Lecture 4)</p> <p>Jake Warden, Melanie Dorey, and Mary Nazzal</p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Discuss potential issues that may arise with engineering controls and containment engineering controls.</li><li>2. Determine downtime procedures for different types of issues and downtimes.</li><li>3. Evaluate the operational procedures needed to resume preparing CSPs.</li></ol>



<p>HD PPE Donning and Doffing (Lecture 5) <b>Melanie Dorey</b> 60 mins</p>	<ol style="list-style-type: none"><li>1. Identify the necessary PPE when handling hazardous drugs and explain why it is required.</li><li>2. Explain the USP 800 requirements and best practice recommendations for PPE donning and doffing.</li><li>3. Outline the sequence of donning and doffing PPE in both a cleanroom and containment segregated compounding area.</li><li>4. Evaluate industry requirements and best practice recommendations for PPE worn during HD compounding.</li></ol>
<p>Receiving, Material Handling and Transport (Lecture 6) <b>Melanie Dorey</b> 45 mins</p>	<ol style="list-style-type: none"><li>1. Summarize work practices essential for reducing hazardous drug contamination and exposure risk during receipt, storage, and transportation.</li><li>2. Explain the USP 800 requirements and best practice recommendations for receiving, storing, and transporting hazardous drugs.</li><li>3. Describe safe transport procedures for hazardous materials and compounded sterile preparations.</li></ol>
<p>HD Spills and Kits (Lecture 7) <b>Melanie Dorey</b> 45 mins</p>	<ol style="list-style-type: none"><li>1. Identify the USP 800 requirements for handling an HD spill.</li><li>2. Describe best practice recommendations for cleaning up a spill.</li><li>3. Discuss the purpose and advantages of using an ancillary HD spill kit.</li></ol>



<p>HD Wipe Sampling (Lecture 8)</p> <p><b>Mark St. Marie</b></p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Define hazardous drug surface wipe sampling and explain its importance.</li><li>2. Outline the differences between quantitative and qualitative wipe sampling.</li><li>3. Develop a hazardous drug wipe sampling program</li></ol>
<p>Medical Surveillance (Lecture 9)</p> <p><b>Mark St. Marie</b></p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Describe the purpose and elements of a medical surveillance program for employees exposed to hazardous drugs.</li><li>2. Discuss the stance of different organizations on developing a medical surveillance program.</li></ol>
<p>Practical Knowledge Check: HD Donning and Doffing (Lab 1)</p> <p><b>Melanie Dorey and Mary Nazzal</b></p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Perform PPE donning and doffing procedures when handling hazardous drugs.</li><li>2. Assess the efficacy of using two pairs of linen shoe covers versus an inner pair of linen shoe covers and an outer pair of seamless water-resistant shoe covers.</li><li>3. Compare the efficacy of using coated versus non-coated HD gowns.</li></ol>
<p>Decontamination, Cleaning and Disinfecting (Lecture 10)</p> <p><b>Melanie Dorey</b></p> <p>45 mins</p>	<ol style="list-style-type: none"><li>1. Define the terms deactivation, decontamination, cleaning, disinfection, and sanitization as they apply to HD compounding environments.</li><li>2. List the types of agents that may be used for decontamination of hazardous drugs.</li><li>3. Properly sequence the cleaning-related activities performed in HD environments.</li></ol>



<p>Compounding HDs (Lecture 11) <b>Melanie Dorey and Fred Massoomi</b> 60 mins</p>	<ol style="list-style-type: none"><li>1. Identify the USP 797 (2023) and USP 800 requirements related to compounding hazardous drugs.</li><li>2. Explain the importance of protecting workers from HD residues during compounding.</li><li>3. Review the key differences between negative pressure technique and the use of a Closed System Transfer Device (CSTD).</li><li>4. Discuss the process for decontaminating and removing the completed CSP from the C-PEC.</li></ol>
<p>Practical Knowledge Check: CSTDs vs. Traditional Compounding (Lab 2) <b>Melanie Dorey and Mary Nazzal</b> 45 mins</p>	<ol style="list-style-type: none"><li>1. Identify both types of compounding methods when preparing hazardous drugs.</li><li>2. Perform simulated compounding using both CSTDs and traditional compounding methods.</li><li>3. Assess the efficiency and safety components of using CSTDs versus traditional compounding methods.</li></ol>